Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Last Name

Contact Us
If you have any questions or feedback please contact us.

Timothy A McKinsey

TitleAssociate Professor
InstitutionUniversity of Colorado Denver - Anschutz Medical Campus

    Collapse Research 
    Collapse research activities and funding
    R21AG043822     (MCKINSEY, TIMOTHY)Sep 30, 2012 - Aug 31, 2014
    Isoform-Selective HDAC Inhibitors for Age-Associated Diastolic Dysfunction
    Role: Principal Investigator

    R21HL113846     (MIYAMOTO, SHELLEY DEANNE)Jan 15, 2013 - Nov 30, 2014
    The Role of Histone Deacytelases in Right Ventricular Adaptation in Hypoplastic L
    Role: Co-Principal Investigator

    R01HL116848     (MCKINSEY, TIMOTHY)Aug 8, 2013 - Jun 30, 2017
    Regulation of Cardiac Signaling by Class I Histone Deacetylases
    Role: Principal Investigator

    S10OD018156     (BUTTRICK, PETER)Jul 1, 2014 - Jun 30, 2015
    Small Animal Ultrasound Imager - Vevo 2100
    Role: Co-Principal Investigator

    R01HL127240     (MCKINSEY, TIMOTHY)Apr 1, 2015 - Mar 31, 2019
    Regulation of Chromatin Signaling in Heart Failure by BET Bromodomain Proteins
    Role: Co-Principal Investigator

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Jeong MY, Lin YH, Wennersten SA, Demos-Davies KM, Cavasin MA, Mahaffey JH, Monzani V, Saripalli C, Mascagni P, Reece TB, Ambardekar AV, Granzier HL, Dinarello CA, McKinsey TA. Histone deacetylase activity governs diastolic dysfunction through a nongenomic mechanism. Sci Transl Med. 2018 Feb 07; 10(427). PMID: 29437146.
      View in: PubMed
    2. Habibian JS, Jefic M, Bagchi RA, Lane RH, McKnight RA, McKinsey TA, Morrison RF, Ferguson BS. DUSP5 functions as a feedback regulator of TNFa-induced ERK1/2 dephosphorylation and inflammatory gene expression in adipocytes. Sci Rep. 2017 Oct 10; 7(1):12879. PMID: 29018280.
      View in: PubMed
    3. Blakeslee WW, Lin YH, Stratton MS, Tatman PD, Hu T, Ferguson BS, McKinsey TA. Class I HDACs control a JIP1-dependent pathway for kinesin-microtubule binding in cardiomyocytes. J Mol Cell Cardiol. 2017 Nov; 112:74-82. PMID: 28886967.
      View in: PubMed
    4. Stratton MS, Koch KA, McKinsey TA. p38a: A Profibrotic Signaling Nexus. Circulation. 2017 Aug 08; 136(6):562-565. PMID: 28784825.
      View in: PubMed
    5. Blakeslee WW, Demos-Davies KM, Lemon DD, Lutter KM, Cavasin MA, Payne S, Nunley K, Long CS, McKinsey TA, Miyamoto SD. Histone deacetylase adaptation in single ventricle heart disease and a young animal model of right ventricular hypertrophy. Pediatr Res. 2017 Oct; 82(4):642-649. PMID: 28549058.
      View in: PubMed
    6. Duan Q, McMahon S, Anand P, Shah H, Thomas S, Salunga HT, Huang Y, Zhang R, Sahadevan A, Lemieux ME, Brown JD, Srivastava D, Bradner JE, McKinsey TA, Haldar SM. BET bromodomain inhibition suppresses innate inflammatory and profibrotic transcriptional networks in heart failure. Sci Transl Med. 2017 May 17; 9(390). PMID: 28515341.
      View in: PubMed
    7. Hooker JM, Strebl MG, Schroeder FA, Wey HY, Ambardekar AV, McKinsey TA, Schoenberger M. Imaging cardiac SCN5A using the novel F-18 radiotracer radiocaine. Sci Rep. 2017 Feb 16; 7:42136. PMID: 28205593.
      View in: PubMed
    8. Schuetze KB, Stratton MS, Blakeslee WW, Wempe MF, Wagner FF, Holson EB, Kuo YM, Andrews AJ, Gilbert TM, Hooker JM, McKinsey TA. Overlapping and Divergent Actions of Structurally Distinct Histone Deacetylase Inhibitors in Cardiac Fibroblasts. J Pharmacol Exp Ther. 2017 Apr; 361(1):140-150. PMID: 28174211.
      View in: PubMed
    9. Zeng Q, Song R, Fullerton DA, Ao L, Zhai Y, Li S, Ballak DB, Cleveland JC, Reece TB, McKinsey TA, Xu D, Dinarello CA, Meng X. Interleukin-37 suppresses the osteogenic responses of human aortic valve interstitial cells in vitro and alleviates valve lesions in mice. Proc Natl Acad Sci U S A. 2017 Feb 14; 114(7):1631-1636. PMID: 28137840.
      View in: PubMed
    10. Aiello RJ, Bourassa PA, Zhang Q, Dubins J, Goldberg DR, De Lombaert S, Humbert M, Guignabert C, Cavasin MA, McKinsey TA, Paralkar V. Tryptophan hydroxylase 1 Inhibition Impacts Pulmonary Vascular Remodeling in Two Rat Models of Pulmonary Hypertension. J Pharmacol Exp Ther. 2017 Feb; 360(2):267-279. PMID: 27927914.
      View in: PubMed
    11. Schuetze KB, Koch KA, McKinsey TA. The potential of targeting epigenetic regulators for the treatment of fibrotic cardiac diseases. Future Med Chem. 2016 09; 8(13):1533-6. PMID: 27556930.
      View in: PubMed
    12. Angiolilli C, Kabala PA, Grabiec AM, Van Baarsen IM, Ferguson BS, García S, Malvar Fernandez B, McKinsey TA, Tak PP, Fossati G, Mascagni P, Baeten DL, Reedquist KA. Histone deacetylase 3 regulates the inflammatory gene expression programme of rheumatoid arthritis fibroblast-like synoviocytes. Ann Rheum Dis. 2017 Jan; 76(1):277-285. PMID: 27457515.
      View in: PubMed
    13. Stratton MS, Lin CY, Anand P, Tatman PD, Ferguson BS, Wickers ST, Ambardekar AV, Sucharov CC, Bradner JE, Haldar SM, McKinsey TA. Signal-Dependent Recruitment of BRD4 to Cardiomyocyte Super-Enhancers Is Suppressed by a MicroRNA. Cell Rep. 2016 08 02; 16(5):1366-1378. PMID: 27425608; PMCID: PMC4972677 [Available on 08/02/17].
    14. Nozik-Grayck E, Woods C, Stearman RS, Venkataraman S, Ferguson BS, Swain K, Bowler RP, Geraci MW, Ihida-Stansbury K, Stenmark KR, McKinsey TA, Domann FE. Histone deacetylation contributes to low extracellular superoxide dismutase expression in human idiopathic pulmonary arterial hypertension. Am J Physiol Lung Cell Mol Physiol. 2016 Jul 01; 311(1):L124-34. PMID: 27233998; PMCID: PMC4967185 [Available on 07/01/17].
    15. Lin YH, Warren CM, Li J, McKinsey TA, Russell B. Myofibril growth during cardiac hypertrophy is regulated through dual phosphorylation and acetylation of the actin capping protein CapZ. Cell Signal. 2016 08; 28(8):1015-24. PMID: 27185186; PMCID: PMC4987081 [Available on 08/01/17].
    16. Reid BG, Stratton MS, Bowers S, Cavasin MA, Demos-Davies KM, Susano I, McKinsey TA. Discovery of novel small molecule inhibitors of cardiac hypertrophy using high throughput, high content imaging. J Mol Cell Cardiol. 2016 Aug; 97:106-13. PMID: 27130278; PMCID: PMC5002372 [Available on 08/01/17].
    17. Horita H, Wysoczynski CL, Walker LA, Moulton KS, Li M, Ostriker A, Tucker R, McKinsey TA, Churchill ME, Nemenoff RA, Weiser-Evans MC. Nuclear PTEN functions as an essential regulator of SRF-dependent transcription to control smooth muscle differentiation. Nat Commun. 2016 Mar 04; 7:10830. PMID: 26940659.
      View in: PubMed
    18. Stratton MS, McKinsey TA. Epigenetic regulation of cardiac fibrosis. J Mol Cell Cardiol. 2016 Mar; 92:206-13. PMID: 26876451; PMCID: PMC4987078 [Available on 03/01/17].
    19. Zhao Y, Londono P, Cao Y, Sharpe EJ, Proenza C, O'Rourke R, Jones KL, Jeong MY, Walker LA, Buttrick PM, McKinsey TA, Song K. High-efficiency reprogramming of fibroblasts into cardiomyocytes requires suppression of pro-fibrotic signalling. Nat Commun. 2015 Sep 10; 6:8243. PMID: 26354680; PMCID: PMC4579788.
    20. Schuetze KB, McKinsey TA. TNAP: a new player in cardiac fibrosis? Focus on "Tissue-nonspecific alkaline phosphatase as a target of sFRP2 in cardiac fibroblasts". Am J Physiol Cell Physiol. 2015 Aug 01; 309(3):C137-8. PMID: 26108666; PMCID: PMC4525085.
    21. Stauffer BL, Dockstader K, Russell G, Hijmans J, Walker L, Cecil M, Demos-Davies K, Medway A, McKinsey TA, Sucharov CC. Transgenic over-expression of YY1 induces pathologic cardiac hypertrophy in a sex-specific manner. Biochem Biophys Res Commun. 2015 Jun 26; 462(2):131-7. PMID: 25935483; PMCID: PMC4449792.
    22. Salian-Mehta S, Xu M, McKinsey TA, Tobet S, Wierman ME. Novel Interaction of Class IIb Histone Deacetylase 6 (HDAC6) with Class IIa HDAC9 Controls Gonadotropin Releasing Hormone (GnRH) Neuronal Cell Survival and Movement. J Biol Chem. 2015 May 29; 290(22):14045-56. PMID: 25873389; PMCID: PMC4447976.
    23. Lemon DD, Harrison BC, Horn TR, Stratton MS, Ferguson BS, Wempe MF, McKinsey TA. Promiscuous actions of small molecule inhibitors of the protein kinase D-class IIa HDAC axis in striated muscle. FEBS Lett. 2015 Apr 28; 589(10):1080-8. PMID: 25816750; PMCID: PMC4410688.
    24. Ferguson BS, McKinsey TA. Non-sirtuin histone deacetylases in the control of cardiac aging. J Mol Cell Cardiol. 2015 Jun; 83:14-20. PMID: 25791169; PMCID: PMC4459895.
    25. Cavasin MA, Stenmark KR, McKinsey TA. Emerging roles for histone deacetylases in pulmonary hypertension and right ventricular remodeling (2013 Grover Conference series). Pulm Circ. 2015 Mar; 5(1):63-72. PMID: 25992271; PMCID: PMC4405717.
    26. Henao-Martínez AF, Agler AH, Watson AM, Hennessy C, Davidson E, Demos-Davies K, McKinsey TA, Wilson M, Schwartz DA, Yang IV. AKT network of genes and impaired myocardial contractility during murine acute Chagasic myocarditis. Am J Trop Med Hyg. 2015 Mar; 92(3):523-9. PMID: 25582694; PMCID: PMC4350542.
    27. Stratton MS, McKinsey TA. Acetyl-lysine erasers and readers in the control of pulmonary hypertension and right ventricular hypertrophy. Biochem Cell Biol. 2015 Apr; 93(2):149-57. PMID: 25707943; PMCID: PMC4975937.
    28. Angiolilli C, Grabiec AM, Ferguson BS, Ospelt C, Malvar Fernandez B, van Es IE, van Baarsen LG, Gay S, McKinsey TA, Tak PP, Baeten DL, Reedquist KA. Inflammatory cytokines epigenetically regulate rheumatoid arthritis fibroblast-like synoviocyte activation by suppressing HDAC5 expression. Ann Rheum Dis. 2016 Feb; 75(2):430-8. PMID: 25452308.
      View in: PubMed
    29. Cavasin MA, Demos-Davies KM, Schuetze KB, Blakeslee WW, Stratton MS, Tuder RM, McKinsey TA. Reversal of severe angioproliferative pulmonary arterial hypertension and right ventricular hypertrophy by combined phosphodiesterase-5 and endothelin receptor inhibition. J Transl Med. 2014 Nov 26; 12:314. PMID: 25425003; PMCID: PMC4255666.
    30. McLendon PM, Ferguson BS, Osinska H, Bhuiyan MS, James J, McKinsey TA, Robbins J. Tubulin hyperacetylation is adaptive in cardiac proteotoxicity by promoting autophagy. Proc Natl Acad Sci U S A. 2014 Dec 02; 111(48):E5178-86. PMID: 25404307; PMCID: PMC4260547.
    31. Konhilas JP, Chen H, Luczak E, McKee LA, Regan J, Watson PA, Stauffer BL, Khalpey ZI, Mckinsey TA, Horn T, LaFleur B, Leinwand LA. Diet and sex modify exercise and cardiac adaptation in the mouse. Am J Physiol Heart Circ Physiol. 2015 Jan 15; 308(2):H135-45. PMID: 25398983; PMCID: PMC4338936.
    32. Blakeslee WW, Wysoczynski CL, Fritz KS, Nyborg JK, Churchill ME, McKinsey TA. Class I HDAC inhibition stimulates cardiac protein SUMOylation through a post-translational mechanism. Cell Signal. 2014 Dec; 26(12):2912-20. PMID: 25220405; PMCID: PMC4252807.
    33. Miyazaki-Anzai S, Masuda M, Demos-Davies KM, Keenan AL, Saunders SJ, Masuda R, Jablonski K, Cavasin MA, Kendrick J, Chonchol M, McKinsey TA, Levi M, Miyazaki M. Endoplasmic reticulum stress effector CCAAT/enhancer-binding protein homologous protein (CHOP) regulates chronic kidney disease-induced vascular calcification. J Am Heart Assoc. 2014 Jun 24; 3(3):e000949. PMID: 24963104; PMCID: PMC4309099.
    34. Demos-Davies KM, Ferguson BS, Cavasin MA, Mahaffey JH, Williams SM, Spiltoir JI, Schuetze KB, Horn TR, Chen B, Ferrara C, Scellini B, Piroddi N, Tesi C, Poggesi C, Jeong MY, McKinsey TA. HDAC6 contributes to pathological responses of heart and skeletal muscle to chronic angiotensin-II signaling. Am J Physiol Heart Circ Physiol. 2014 Jul 15; 307(2):H252-8. PMID: 24858848; PMCID: PMC4101640.
    35. Haldar SM, McKinsey TA. BET-ting on chromatin-based therapeutics for heart failure. J Mol Cell Cardiol. 2014 Sep; 74:98-102. PMID: 24838003; PMCID: PMC4115033.
    36. Schuetze KB, McKinsey TA, Long CS. Targeting cardiac fibroblasts to treat fibrosis of the heart: focus on HDACs. J Mol Cell Cardiol. 2014 May; 70:100-7. PMID: 24631770; PMCID: PMC4080911.
    37. Williams SM, Golden-Mason L, Ferguson BS, Schuetze KB, Cavasin MA, Demos-Davies K, Yeager ME, Stenmark KR, McKinsey TA. Class I HDACs regulate angiotensin II-dependent cardiac fibrosis via fibroblasts and circulating fibrocytes. J Mol Cell Cardiol. 2014 Feb; 67:112-25. PMID: 24374140; PMCID: PMC4120952.
    38. Pedram A, Razandi M, Narayanan R, Dalton JT, McKinsey TA, Levin ER. Estrogen regulates histone deacetylases to prevent cardiac hypertrophy. Mol Biol Cell. 2013 Dec; 24(24):3805-18. PMID: 24152730; PMCID: PMC3861078.
    39. Wang D, Zhang H, Li M, Frid MG, Flockton AR, McKeon BA, Yeager ME, Fini MA, Morrell NW, Pullamsetti SS, Velegala S, Seeger W, McKinsey TA, Sucharov CC, Stenmark KR. MicroRNA-124 controls the proliferative, migratory, and inflammatory phenotype of pulmonary vascular fibroblasts. Circ Res. 2014 Jan 03; 114(1):67-78. PMID: 24122720; PMCID: PMC4117588.
    40. Spiltoir JI, Stratton MS, Cavasin MA, Demos-Davies K, Reid BG, Qi J, Bradner JE, McKinsey TA. BET acetyl-lysine binding proteins control pathological cardiac hypertrophy. J Mol Cell Cardiol. 2013 Oct; 63:175-9. PMID: 23939492; PMCID: PMC4089995.
    41. Ferguson BS, Harrison BC, Jeong MY, Reid BG, Wempe MF, Wagner FF, Holson EB, McKinsey TA. Signal-dependent repression of DUSP5 by class I HDACs controls nuclear ERK activity and cardiomyocyte hypertrophy. Proc Natl Acad Sci U S A. 2013 Jun 11; 110(24):9806-11. PMID: 23720316; PMCID: PMC3683796.
    42. Kadam RS, Ramamoorthy P, LaFlamme DJ, McKinsey TA, Kompella UB. Hypoxia alters ocular drug transporter expression and activity in rat and calf models: implications for drug delivery. Mol Pharm. 2013 Jun 03; 10(6):2350-61. PMID: 23607566; PMCID: PMC3973437.
    43. Zhao L, Chen CN, Hajji N, Oliver E, Cotroneo E, Wharton J, Wilkins MR, Wang D, Li M, Stenmark KR, McKinsey TA, Buttrick P. Response to letter regarding article, “histone deacetylation inhibition in pulmonary hypertension: therapeutic potential of valproic acid and suberoylanilide hydroxamic acid”. Circulation. 2013 Apr 09; 127(14):e540. PMID: 23691553.
      View in: PubMed
    44. Ramjiawan A, Bagchi RA, Blant A, Albak L, Cavasin MA, Horn TR, McKinsey TA, Czubryt MP. Roles of histone deacetylation and AMP kinase in regulation of cardiomyocyte PGC-1a gene expression in hypoxia. Am J Physiol Cell Physiol. 2013 Jun 01; 304(11):C1064-72. PMID: 23515531.
      View in: PubMed
    45. Zhao L, Chen CN, Hajji N, Oliver E, Cotroneo E, Wharton J, Wang D, Li M, McKinsey TA, Stenmark KR, Wilkins MR. Histone deacetylation inhibition in pulmonary hypertension: therapeutic potential of valproic acid and suberoylanilide hydroxamic acid. Circulation. 2012 Jul 24; 126(4):455-67. PMID: 22711276; PMCID: PMC3799888.
    46. Cavasin MA, Demos-Davies K, Horn TR, Walker LA, Lemon DD, Birdsey N, Weiser-Evans MC, Harral J, Irwin DC, Anwar A, Yeager ME, Li M, Watson PA, Nemenoff RA, Buttrick PM, Stenmark KR, McKinsey TA. Selective class I histone deacetylase inhibition suppresses hypoxia-induced cardiopulmonary remodeling through an antiproliferative mechanism. Circ Res. 2012 Mar 02; 110(5):739-48. PMID: 22282194; PMCID: PMC3682822.
    47. Stenmark KR, Frid MG, Yeager M, Li M, Riddle S, McKinsey T, El Kasmi KC. Targeting the adventitial microenvironment in pulmonary hypertension: A potential approach to therapy that considers epigenetic change. Pulm Circ. 2012 Jan-Mar; 2(1):3-14. PMID: 22558514; PMCID: PMC3342746.
    48. McKinsey TA. Therapeutic potential for HDAC inhibitors in the heart. Annu Rev Pharmacol Toxicol. 2012; 52:303-19. PMID: 21942627.
      View in: PubMed
    49. Li M, Riddle SR, Frid MG, El Kasmi KC, McKinsey TA, Sokol RJ, Strassheim D, Meyrick B, Yeager ME, Flockton AR, McKeon BA, Lemon DD, Horn TR, Anwar A, Barajas C, Stenmark KR. Emergence of fibroblasts with a proinflammatory epigenetically altered phenotype in severe hypoxic pulmonary hypertension. J Immunol. 2011 Sep 01; 187(5):2711-22. PMID: 21813768; PMCID: PMC3159707.
    50. Phan D, Stratton MS, Huynh QK, McKinsey TA. A novel protein kinase C target site in protein kinase D is phosphorylated in response to signals for cardiac hypertrophy. Biochem Biophys Res Commun. 2011 Jul 29; 411(2):335-41. PMID: 21726532.
      View in: PubMed
    51. Lemon DD, Horn TR, Cavasin MA, Jeong MY, Haubold KW, Long CS, Irwin DC, McCune SA, Chung E, Leinwand LA, McKinsey TA. Cardiac HDAC6 catalytic activity is induced in response to chronic hypertension. J Mol Cell Cardiol. 2011 Jul; 51(1):41-50. PMID: 21539845; PMCID: PMC3113526.
    52. Sucharov CC, Dockstader K, Nunley K, McKinsey TA, Bristow M. ß-Adrenergic receptor stimulation and activation of protein kinase A protect against a1-adrenergic-mediated phosphorylation of protein kinase D and histone deacetylase 5. J Card Fail. 2011 Jul; 17(7):592-600. PMID: 21703532; PMCID: PMC3128428.
    53. McKinsey TA. Targeting inflammation in heart failure with histone deacetylase inhibitors. Mol Med. 2011 May-Jun; 17(5-6):434-41. PMID: 21267510; PMCID: PMC3105143.
    54. Gamber GG, Meredith E, Zhu Q, Yan W, Rao C, Capparelli M, Burgis R, Enyedy I, Zhang JH, Soldermann N, Beattie K, Rozhitskaya O, Koch KA, Pagratis N, Hosagrahara V, Vega RB, McKinsey TA, Monovich L. 3,5-diarylazoles as novel and selective inhibitors of protein kinase D. Bioorg Med Chem Lett. 2011 Mar 01; 21(5):1447-51. PMID: 21300545.
      View in: PubMed
    55. McKinsey TA. The biology and therapeutic implications of HDACs in the heart. Handb Exp Pharmacol. 2011; 206:57-78. PMID: 21879446.
      View in: PubMed
    56. McKinsey TA. Isoform-selective HDAC inhibitors: closing in on translational medicine for the heart. J Mol Cell Cardiol. 2011 Oct; 51(4):491-6. PMID: 21108947.
      View in: PubMed
    57. Lemon DD, Papst PJ, Joly K, Plato CF, McKinsey TA. A high-performance liquid chromatography assay for quantification of cardiac myosin heavy chain isoform protein expression. Anal Biochem. 2011 Jan 01; 408(1):132-5. PMID: 20816744.
      View in: PubMed
    58. Meredith EL, Beattie K, Burgis R, Capparelli M, Chapo J, Dipietro L, Gamber G, Enyedy I, Hood DB, Hosagrahara V, Jewell C, Koch KA, Lee W, Lemon DD, McKinsey TA, Miranda K, Pagratis N, Phan D, Plato C, Rao C, Rozhitskaya O, Soldermann N, Springer C, van Eis M, Vega RB, Yan W, Zhu Q, Monovich LG. Identification of potent and selective amidobipyridyl inhibitors of protein kinase D. J Med Chem. 2010 Aug 12; 53(15):5422-38. PMID: 20684592.
      View in: PubMed
    59. Meredith EL, Ardayfio O, Beattie K, Dobler MR, Enyedy I, Gaul C, Hosagrahara V, Jewell C, Koch K, Lee W, Lehmann H, McKinsey TA, Miranda K, Pagratis N, Pancost M, Patnaik A, Phan D, Plato C, Qian M, Rajaraman V, Rao C, Rozhitskaya O, Ruppen T, Shi J, Siska SJ, Springer C, van Eis M, Vega RB, von Matt A, Yang L, Yoon T, Zhang JH, Zhu N, Monovich LG. Identification of orally available naphthyridine protein kinase D inhibitors. J Med Chem. 2010 Aug 12; 53(15):5400-21. PMID: 20684591.
      View in: PubMed
    60. Harrison BC, Huynh K, Lundgaard GL, Helmke SM, Perryman MB, McKinsey TA. Protein kinase C-related kinase targets nuclear localization signals in a subset of class IIa histone deacetylases. FEBS Lett. 2010 Mar 19; 584(6):1103-10. PMID: 20188095.
      View in: PubMed
    61. Bush EW, McKinsey TA. Protein acetylation in the cardiorenal axis: the promise of histone deacetylase inhibitors. Circ Res. 2010 Feb 05; 106(2):272-84. PMID: 20133912.
      View in: PubMed
    62. Monovich L, Vega RB, Meredith E, Miranda K, Rao C, Capparelli M, Lemon DD, Phan D, Koch KA, Chapo JA, Hood DB, McKinsey TA. A novel kinase inhibitor establishes a predominant role for protein kinase D as a cardiac class IIa histone deacetylase kinase. FEBS Lett. 2010 Feb 05; 584(3):631-7. PMID: 20018189.
      View in: PubMed
    63. Calalb MB, McKinsey TA, Newkirk S, Huynh K, Sucharov CC, Bristow MR. Increased phosphorylation-dependent nuclear export of class II histone deacetylases in failing human heart. Clin Transl Sci. 2009 Oct; 2(5):325-32. PMID: 20443916.
      View in: PubMed
    64. Bush EW, McKinsey TA. Targeting histone deacetylases for heart failure. Expert Opin Ther Targets. 2009 Jul; 13(7):767-84. PMID: 19466913.
      View in: PubMed
    65. Monovich L, Koch KA, Burgis R, Osimboni E, Mann T, Wall D, Gao J, Feng Y, Vega RB, Turner BA, Hood DB, Law A, Papst PJ, Koditek D, Chapo JA, Reid BG, Melvin LS, Pagratis NC, McKinsey TA. Suppression of HDAC nuclear export and cardiomyocyte hypertrophy by novel irreversible inhibitors of CRM1. Biochim Biophys Acta. 2009 May; 1789(5):422-31. PMID: 19414071.
      View in: PubMed
    66. Sucharov CC, Dockstader K, McKinsey TA. YY1 protects cardiac myocytes from pathologic hypertrophy by interacting with HDAC5. Mol Biol Cell. 2008 Oct; 19(10):4141-53. PMID: 18632988; PMCID: PMC2555926.
    67. Kim MS, Fielitz J, McAnally J, Shelton JM, Lemon DD, McKinsey TA, Richardson JA, Bassel-Duby R, Olson EN. Protein kinase D1 stimulates MEF2 activity in skeletal muscle and enhances muscle performance. Mol Cell Biol. 2008 Jun; 28(11):3600-9. PMID: 18378694; PMCID: PMC2423294.
    68. Backs J, Backs T, Bezprozvannaya S, McKinsey TA, Olson EN. Histone deacetylase 5 acquires calcium/calmodulin-dependent kinase II responsiveness by oligomerization with histone deacetylase 4. Mol Cell Biol. 2008 May; 28(10):3437-45. PMID: 18332106; PMCID: PMC2423150.
    69. Ha CH, Wang W, Jhun BS, Wong C, Hausser A, Pfizenmaier K, McKinsey TA, Olson EN, Jin ZG. Protein kinase D-dependent phosphorylation and nuclear export of histone deacetylase 5 mediates vascular endothelial growth factor-induced gene expression and angiogenesis. J Biol Chem. 2008 May 23; 283(21):14590-9. PMID: 18332134; PMCID: PMC2386927.
    70. Renthal W, Maze I, Krishnan V, Covington HE, Xiao G, Kumar A, Russo SJ, Graham A, Tsankova N, Kippin TE, Kerstetter KA, Neve RL, Haggarty SJ, McKinsey TA, Bassel-Duby R, Olson EN, Nestler EJ. Histone deacetylase 5 epigenetically controls behavioral adaptations to chronic emotional stimuli. Neuron. 2007 Nov 08; 56(3):517-29. PMID: 17988634.
      View in: PubMed
    71. Xu X, Ha CH, Wong C, Wang W, Hausser A, Pfizenmaier K, Olson EN, McKinsey TA, Jin ZG. Angiotensin II stimulates protein kinase D-dependent histone deacetylase 5 phosphorylation and nuclear export leading to vascular smooth muscle cell hypertrophy. Arterioscler Thromb Vasc Biol. 2007 Nov; 27(11):2355-62. PMID: 17823368; PMCID: PMC4259271.
    72. McKinsey TA, Kass DA. Small-molecule therapies for cardiac hypertrophy: moving beneath the cell surface. Nat Rev Drug Discov. 2007 Aug; 6(8):617-35. PMID: 17643091.
      View in: PubMed
    73. McKinsey TA. Derepression of pathological cardiac genes by members of the CaM kinase superfamily. Cardiovasc Res. 2007 Mar 01; 73(4):667-77. PMID: 17217938.
      View in: PubMed
    74. Bush EW, Hood DB, Papst PJ, Chapo JA, Minobe W, Bristow MR, Olson EN, McKinsey TA. Canonical transient receptor potential channels promote cardiomyocyte hypertrophy through activation of calcineurin signaling. J Biol Chem. 2006 Nov 03; 281(44):33487-96. PMID: 16950785.
      View in: PubMed
    75. Harrison BC, Kim MS, van Rooij E, Plato CF, Papst PJ, Vega RB, McAnally JA, Richardson JA, Bassel-Duby R, Olson EN, McKinsey TA. Regulation of cardiac stress signaling by protein kinase d1. Mol Cell Biol. 2006 May; 26(10):3875-88. PMID: 16648482; PMCID: PMC1488991.
    76. Huynh QK, McKinsey TA. Protein kinase D directly phosphorylates histone deacetylase 5 via a random sequential kinetic mechanism. Arch Biochem Biophys. 2006 Jun 15; 450(2):141-8. PMID: 16584705.
      View in: PubMed
    77. Wu X, Zhang T, Bossuyt J, Li X, McKinsey TA, Dedman JR, Olson EN, Chen J, Brown JH, Bers DM. Local InsP3-dependent perinuclear Ca2+ signaling in cardiac myocyte excitation-transcription coupling. J Clin Invest. 2006 Mar; 116(3):675-82. PMID: 16511602; PMCID: PMC1386110.
    78. Matthews SA, Liu P, Spitaler M, Olson EN, McKinsey TA, Cantrell DA, Scharenberg AM. Essential role for protein kinase D family kinases in the regulation of class II histone deacetylases in B lymphocytes. Mol Cell Biol. 2006 Feb; 26(4):1569-77. PMID: 16449666; PMCID: PMC1367196.
    79. Olson EN, Backs J, McKinsey TA. Control of cardiac hypertrophy and heart failure by histone acetylation/deacetylation. Novartis Found Symp. 2006; 274:3-12; discussion 13-9, 152-5, 272-6. PMID: 17019803.
      View in: PubMed
    80. McKinsey TA, Kuwahara K, Bezprozvannaya S, Olson EN. Class II histone deacetylases confer signal responsiveness to the ankyrin-repeat proteins ANKRA2 and RFXANK. Mol Biol Cell. 2006 Jan; 17(1):438-47. PMID: 16236793; PMCID: PMC1345680.
    81. McKinsey TA, Olson EN. Toward transcriptional therapies for the failing heart: chemical screens to modulate genes. J Clin Invest. 2005 Mar; 115(3):538-46. PMID: 15765135; PMCID: PMC1052006.
    82. Parra M, Kasler H, McKinsey TA, Olson EN, Verdin E. Protein kinase D1 phosphorylates HDAC7 and induces its nuclear export after T-cell receptor activation. J Biol Chem. 2005 Apr 08; 280(14):13762-70. PMID: 15623513.
      View in: PubMed
    83. Harrison BC, Roberts CR, Hood DB, Sweeney M, Gould JM, Bush EW, McKinsey TA. The CRM1 nuclear export receptor controls pathological cardiac gene expression. Mol Cell Biol. 2004 Dec; 24(24):10636-49. PMID: 15572669; PMCID: PMC533968.
    84. Chang S, McKinsey TA, Zhang CL, Richardson JA, Hill JA, Olson EN. Histone deacetylases 5 and 9 govern responsiveness of the heart to a subset of stress signals and play redundant roles in heart development. Mol Cell Biol. 2004 Oct; 24(19):8467-76. PMID: 15367668; PMCID: PMC516756.
    85. Vega RB, Harrison BC, Meadows E, Roberts CR, Papst PJ, Olson EN, McKinsey TA. Protein kinases C and D mediate agonist-dependent cardiac hypertrophy through nuclear export of histone deacetylase 5. Mol Cell Biol. 2004 Oct; 24(19):8374-85. PMID: 15367659; PMCID: PMC516754.
    86. McKinsey TA, Olson EN. Cardiac histone acetylation--therapeutic opportunities abound. Trends Genet. 2004 Apr; 20(4):206-13. PMID: 15041175.
      View in: PubMed
    87. Bush E, Fielitz J, Melvin L, Martinez-Arnold M, McKinsey TA, Plichta R, Olson EN. A small molecular activator of cardiac hypertrophy uncovered in a chemical screen for modifiers of the calcineurin signaling pathway. Proc Natl Acad Sci U S A. 2004 Mar 02; 101(9):2870-5. PMID: 14976250; PMCID: PMC365712.
    88. McKinsey TA, Olson EN. Dual roles of histone deacetylases in the control of cardiac growth. Novartis Found Symp. 2004; 259:132-41; discussion 141-5, 163-9. PMID: 15171251.
      View in: PubMed
    89. Antos CL, McKinsey TA, Dreitz M, Hollingsworth LM, Zhang CL, Schreiber K, Rindt H, Gorczynski RJ, Olson EN. Dose-dependent blockade to cardiomyocyte hypertrophy by histone deacetylase inhibitors. J Biol Chem. 2003 Aug 01; 278(31):28930-7. PMID: 12761226.
      View in: PubMed
    90. McKinsey TA, Zhang CL, Olson EN. Signaling chromatin to make muscle. Curr Opin Cell Biol. 2002 Dec; 14(6):763-72. PMID: 12473352.
      View in: PubMed
    91. Zhang CL, McKinsey TA, Olson EN. Association of class II histone deacetylases with heterochromatin protein 1: potential role for histone methylation in control of muscle differentiation. Mol Cell Biol. 2002 Oct; 22(20):7302-12. PMID: 12242305; PMCID: PMC139799.
    92. Zhang CL, McKinsey TA, Chang S, Antos CL, Hill JA, Olson EN. Class II histone deacetylases act as signal-responsive repressors of cardiac hypertrophy. Cell. 2002 Aug 23; 110(4):479-88. PMID: 12202037; PMCID: PMC4459650.
    93. Antos CL, McKinsey TA, Frey N, Kutschke W, McAnally J, Shelton JM, Richardson JA, Hill JA, Olson EN. Activated glycogen synthase-3 beta suppresses cardiac hypertrophy in vivo. Proc Natl Acad Sci U S A. 2002 Jan 22; 99(2):907-12. PMID: 11782539; PMCID: PMC117404.
    94. McKinsey TA, Zhang CL, Olson EN. MEF2: a calcium-dependent regulator of cell division, differentiation and death. Trends Biochem Sci. 2002 Jan; 27(1):40-7. PMID: 11796223.
      View in: PubMed
    95. McKinsey TA, Zhang CL, Olson EN. Control of muscle development by dueling HATs and HDACs. Curr Opin Genet Dev. 2001 Oct; 11(5):497-504. PMID: 11532390.
      View in: PubMed
    96. McKinsey TA, Zhang CL, Olson EN. Identification of a signal-responsive nuclear export sequence in class II histone deacetylases. Mol Cell Biol. 2001 Sep; 21(18):6312-21. PMID: 11509672; PMCID: PMC87361.
    97. Zhang CL, McKinsey TA, Olson EN. The transcriptional corepressor MITR is a signal-responsive inhibitor of myogenesis. Proc Natl Acad Sci U S A. 2001 Jun 19; 98(13):7354-9. PMID: 11390982; PMCID: PMC34672.
    98. Rothermel BA, McKinsey TA, Vega RB, Nicol RL, Mammen P, Yang J, Antos CL, Shelton JM, Bassel-Duby R, Olson EN, Williams RS. Myocyte-enriched calcineurin-interacting protein, MCIP1, inhibits cardiac hypertrophy in vivo. Proc Natl Acad Sci U S A. 2001 Mar 13; 98(6):3328-33. PMID: 11248078; PMCID: PMC30653.
    99. Zhang CL, McKinsey TA, Lu JR, Olson EN. Association of COOH-terminal-binding protein (CtBP) and MEF2-interacting transcription repressor (MITR) contributes to transcriptional repression of the MEF2 transcription factor. J Biol Chem. 2001 Jan 05; 276(1):35-9. PMID: 11022042.
      View in: PubMed
    100. McKinsey TA, Zhang CL, Olson EN. Activation of the myocyte enhancer factor-2 transcription factor by calcium/calmodulin-dependent protein kinase-stimulated binding of 14-3-3 to histone deacetylase 5. Proc Natl Acad Sci U S A. 2000 Dec 19; 97(26):14400-5. PMID: 11114197; PMCID: PMC18930.
    101. Yang J, Rothermel B, Vega RB, Frey N, McKinsey TA, Olson EN, Bassel-Duby R, Williams RS. Independent signals control expression of the calcineurin inhibitory proteins MCIP1 and MCIP2 in striated muscles. Circ Res. 2000 Dec 08; 87(12):E61-8. PMID: 11110780.
      View in: PubMed
    102. McKinsey TA, Zhang CL, Lu J, Olson EN. Signal-dependent nuclear export of a histone deacetylase regulates muscle differentiation. Nature. 2000 Nov 02; 408(6808):106-11. PMID: 11081517; PMCID: PMC4459600.
    103. Frey N, McKinsey TA, Olson EN. Decoding calcium signals involved in cardiac growth and function. Nat Med. 2000 Nov; 6(11):1221-7. PMID: 11062532.
      View in: PubMed
    104. McKinsey TA, Chu Z, Tedder TF, Ballard DW. Transcription factor NF-kappaB regulates inducible CD83 gene expression in activated T lymphocytes. Mol Immunol. 2000 Aug-Sep; 37(12-13):783-8. PMID: 11275263.
      View in: PubMed
    105. Lu J, McKinsey TA, Zhang CL, Olson EN. Regulation of skeletal myogenesis by association of the MEF2 transcription factor with class II histone deacetylases. Mol Cell. 2000 Aug; 6(2):233-44. PMID: 10983972.
      View in: PubMed
    106. Wu H, Naya FJ, McKinsey TA, Mercer B, Shelton JM, Chin ER, Simard AR, Michel RN, Bassel-Duby R, Olson EN, Williams RS. MEF2 responds to multiple calcium-regulated signals in the control of skeletal muscle fiber type. EMBO J. 2000 May 02; 19(9):1963-73. PMID: 10790363; PMCID: PMC305686.
    107. Passier R, Zeng H, Frey N, Naya FJ, Nicol RL, McKinsey TA, Overbeek P, Richardson JA, Grant SR, Olson EN. CaM kinase signaling induces cardiac hypertrophy and activates the MEF2 transcription factor in vivo. J Clin Invest. 2000 May; 105(10):1395-406. PMID: 10811847; PMCID: PMC315462.
    108. Lu J, McKinsey TA, Nicol RL, Olson EN. Signal-dependent activation of the MEF2 transcription factor by dissociation from histone deacetylases. Proc Natl Acad Sci U S A. 2000 Apr 11; 97(8):4070-5. PMID: 10737771; PMCID: PMC18151.
    109. Jo H, Zhang R, Zhang H, McKinsey TA, Shao J, Beauchamp RD, Ballard DW, Liang P. NF-kappa B is required for H-ras oncogene induced abnormal cell proliferation and tumorigenesis. Oncogene. 2000 Feb 17; 19(7):841-9. PMID: 10702792.
      View in: PubMed
    110. McKinsey TA, Olson EN. Cardiac hypertrophy: sorting out the circuitry. Curr Opin Genet Dev. 1999 Jun; 9(3):267-74. PMID: 10377279.
      View in: PubMed
    111. Lu JR, McKinsey TA, Xu H, Wang DZ, Richardson JA, Olson EN. FOG-2, a heart- and brain-enriched cofactor for GATA transcription factors. Mol Cell Biol. 1999 Jun; 19(6):4495-502. PMID: 10330188; PMCID: PMC104407.
    112. Meguro T, Hong C, Asai K, Takagi G, McKinsey TA, Olson EN, Vatner SF. Cyclosporine attenuates pressure-overload hypertrophy in mice while enhancing susceptibility to decompensation and heart failure. Circ Res. 1999 Apr 02; 84(6):735-40. PMID: 10189362.
      View in: PubMed
    113. Chu ZL, McKinsey TA, Liu L, Gentry JJ, Malim MH, Ballard DW. Suppression of tumor necrosis factor-induced cell death by inhibitor of apoptosis c-IAP2 is under NF-kappaB control. Proc Natl Acad Sci U S A. 1997 Sep 16; 94(19):10057-62. PMID: 9294162; PMCID: PMC23303.
    114. McKinsey TA, Chu ZL, Ballard DW. Phosphorylation of the PEST domain of IkappaBbeta regulates the function of NF-kappaB/IkappaBbeta complexes. J Biol Chem. 1997 Sep 05; 272(36):22377-80. PMID: 9278383.
      View in: PubMed
    115. Sachdev S, Diehl JA, McKinsey TA, Hans A, Hannink M. A threshold nuclear level of the v-Rel oncoprotein is required for transformation of avian lymphocytes. Oncogene. 1997 May 29; 14(21):2585-94. PMID: 9191058.
      View in: PubMed
    116. Chu ZL, McKinsey TA, Liu L, Qi X, Ballard DW. Basal phosphorylation of the PEST domain in the I(kappa)B(beta) regulates its functional interaction with the c-rel proto-oncogene product. Mol Cell Biol. 1996 Nov; 16(11):5974-84. PMID: 8887627; PMCID: PMC231600.
    117. Rottjakob EM, Sachdev S, Leanna CA, McKinsey TA, Hannink M. PEST-dependent cytoplasmic retention of v-Rel by I(kappa)B-alpha: evidence that I(kappa)B-alpha regulates cellular localization of c-Rel and v-Rel by distinct mechanisms. J Virol. 1996 May; 70(5):3176-88. PMID: 8627798; PMCID: PMC190181.
    118. McKinsey TA, Brockman JA, Scherer DC, Al-Murrani SW, Green PL, Ballard DW. Inactivation of IkappaBbeta by the tax protein of human T-cell leukemia virus type 1: a potential mechanism for constitutive induction of NF-kappaB. Mol Cell Biol. 1996 May; 16(5):2083-90. PMID: 8628274; PMCID: PMC231195.
    119. Brockman JA, Scherer DC, McKinsey TA, Hall SM, Qi X, Lee WY, Ballard DW. Coupling of a signal response domain in I kappa B alpha to multiple pathways for NF-kappa B activation. Mol Cell Biol. 1995 May; 15(5):2809-18. PMID: 7739562; PMCID: PMC230512.
    120. Sorkin A, McKinsey T, Shih W, Kirchhausen T, Carpenter G. Stoichiometric interaction of the epidermal growth factor receptor with the clathrin-associated protein complex AP-2. J Biol Chem. 1995 Jan 13; 270(2):619-25. PMID: 7822287.
      View in: PubMed
    121. Diehl JA, McKinsey TA, Hannink M. Differential pp40I kappa B-beta inhibition of DNA binding by rel proteins. Mol Cell Biol. 1993 Mar; 13(3):1769-78. PMID: 8441412; PMCID: PMC359489.
    McKinsey's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    Co-Authors Expand Description
    Similar People Expand Description
    Same Department Expand Description
    Physical Neighbors Expand Description

    Copyright © 2017 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.10.0)